Bristol-Myers Squibb Company (BMY) Shares Bought by Beacon Financial Group
Beacon Financial Group boosted its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 1.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 96,488 shares of the biopharmaceutical company’s stock after acquiring an additional 1,541 shares during the quarter. Beacon Financial Group’s holdings in Bristol-Myers Squibb were worth $3,985,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of BMY. Connecticut Wealth Management LLC bought a new stake in Bristol-Myers Squibb during the 1st quarter worth about $224,000. Birmingham Capital Management Co. Inc. AL lifted its position in Bristol-Myers Squibb by 4.4% during the 1st quarter. Birmingham Capital Management Co. Inc. AL now owns 70,973 shares of the biopharmaceutical company’s stock valued at $3,860,000 after purchasing an additional 3,000 shares during the period. HGK Asset Management Inc. lifted its position in Bristol-Myers Squibb by 20.8% during the 1st quarter. HGK Asset Management Inc. now owns 308,825 shares of the biopharmaceutical company’s stock valued at $16,794,000 after purchasing an additional 53,221 shares during the period. Investment Partners Ltd. OH ADV lifted its position in Bristol-Myers Squibb by 1.4% during the 1st quarter. Investment Partners Ltd. OH ADV now owns 20,350 shares of the biopharmaceutical company’s stock valued at $1,107,000 after purchasing an additional 274 shares during the period. Finally, Goelzer Investment Management Inc. lifted its position in Bristol-Myers Squibb by 85.4% during the 1st quarter. Goelzer Investment Management Inc. now owns 75,402 shares of the biopharmaceutical company’s stock valued at $4,100,000 after purchasing an additional 34,735 shares during the period. 69.82% of the stock is currently owned by hedge funds and other institutional investors.
In related news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the sale, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at $585,033.24. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at $62.41 on Friday. The firm has a market cap of $102,154.63, a P/E ratio of 21.09, a P/E/G ratio of 2.37 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The firm had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business’s revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.77 earnings per share. research analysts predict that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.56%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 61.42%.
A number of research analysts have issued reports on the stock. Vetr downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 target price on the stock. in a research report on Thursday, September 28th. Jefferies Group restated a “buy” rating and set a $72.00 target price on shares of Bristol-Myers Squibb in a research report on Wednesday, September 27th. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a research report on Monday, December 11th. Piper Jaffray Companies restated a “hold” rating and set a $60.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Finally, Cowen restated a “hold” rating and set a $65.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, September 19th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $64.93.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/12/17/bristol-myers-squibb-company-bmy-shares-bought-by-beacon-financial-group.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.